Long term disease free survival in advanced melanomas treated with nitrosoureas: Mechanisms and new perspectives

BMC Cancer

Volumn 5, Issue , 2005, Pages

  Durando, Xavier ^a   Thivat, Emilie ^a   D'Incan, Michel ^b   Sinsard, Anne ^a   Madelmont, Jean Claude ^c   Chollet, Philippe ^a  

^a CENTRE JEAN PERRIN   (France)

^b HÔTEL DIEU   (France)

^c INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BLEOMYCIN; CARMUSTINE; CHLOROETHYLNITROSOUREA; CISPLATIN; CYSTEMUSTINE; DACARBAZINE; LOMUSTINE; PROCARBAZINE; SEMUSTINE; TAMOXIFEN; VINBLASTINE; VINCRISTINE; VINDESINE; ANTINEOPLASTIC AGENT; N' (2 CHLOROETHYL) N (2 (METHYLSULFONYL)ETHYL) N' NITROSOUREA; N'-(2-CHLOROETHYL)-N-(2-(METHYLSULFONYL)ETHYL)-N'-NITROSOUREA; NITROSOUREA DERIVATIVE;

ADULT; ALLERGIC REACTION; APLASIA; ARTICLE; BLOOD TRANSFUSION; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SURGERY; CANCER SURVIVAL; CLINICAL FEATURE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG RESPONSE; ERYTHROCYTE TRANSFUSION; FEMALE; HEMATOLOGIC DISEASE; HUMAN; INFORMED CONSENT; INOPERABLE CANCER; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; MELANOMA; MULTICENTER STUDY; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUTROPENIA; PROFESSIONAL STANDARD; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; VOMITING; WORLD HEALTH ORGANIZATION; CASE REPORT; CLINICAL TRIAL (TOPIC); DISEASE FREE SURVIVAL; METASTASIS; MIDDLE AGED; MORTALITY; REMISSION; SKIN TUMOR; TIME; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; NITROSOUREA COMPOUNDS; REMISSION INDUCTION; SKIN NEOPLASMS; TIME FACTORS; TREATMENT OUTCOME;

EID: 28044448277     PISSN: 14712407     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-5-147     Document Type: Article

References (14)

1. Bajetta E, Del Vecchio M, Bernard-Marty C, Vitali M, Buzzoni R, Rixe O, Nova P, Aglione S, Taillibert S, Khayat D: Metastatic melanoma: chemotherapy. Semin Oncol 2002, 29:427-445.
2. Hill G J, 2nd, Krementz E T, Hill H Z: Dimethyl triazeno imidazole carboxamide and combination therapy for melanoma. IV. Late results after complete response to chemotherapy (Central Oncology Group protocols 7130, 7131, and 7131A). Cancer 1984, 53:1299-1305.
3. Berd D, Mastrangelo M J: Combination chemotherapy of metastatic melanoma. J Clin Oncol 1995, 13:796-797.
4. Coates A S, Segelov E: Long term response to chemotherapy in patients with visceral metastatic melanoma. Ann Oncol 1994, 5:249-251.
5. Petit T, Borel C, Rixe O, Avril M F, Monnier A, Giroux B, Weil M, Khayat D: Complete remission seven years after treatment for metastatic malignant melanoma. Cancer 1996, 77:900-902.
6. Samuel L M, Harvey V J, Mitchell P L, Thompson P I, Mak D, Melville P, Evans B D: Phase II trial of procarbazine, vincristine and lomustine (POC) chemotherapy in metastatic cutaneous malignant melanoma. Eur J Cancer 1994, 30A:2054-2056.
7. Godeneche D, Madelmont J C, Moreau M F, Duprat J, Plague R, Meyniel G: Metabolism of 2-chloroethyl nitrosocarbamoylcystamine by rat liver subcellular fractions. Drug Metab Dispos 1986, 14:112-117.
8. Filippeschi S, Colombo T, Bassani D, De Francesco L, Arioli P, D'Incalci M, Bartosek I, Guaitani A: Antitumor activity of the novel nitrosourea S10036 in rodent tumors. Anticancer Res. 1988, 8:1351-1354.
9. Ahmann D L, Creagan E T, Hahn R G, Edmonson J H, Bisel H F, Schaid D J: Complete responses and long-term survivals after systemic chemotherapy for patients with advanced malignant melanoma. Cancer 1989, 63:224-227.
10. Demidem A, Morvan D, Papon J, De Latour M, Madelmont J C: Cystemustine induces redifferentiation of primary tumors and confers protection against secondary tumor growth in a melanoma murine model. Cancer Res 2001, 61:2294-2300.
11. Paz M F, Yaya-Tur R, Rojas-Marcos I, Reynes G, Pollan M, Aguirre-Cruz L, Garcia-Lopez J L, Piquer J, Safont M J, Balana C, Sanchez-Cespedes M, Garcia-Villanueva M, Arribas L, Esteller M: CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas. Clin Cancer Res 2004, 10:4933-4938.
12. Cellarier E, Terret C, Labarre P, Ouabdesselam R, Cure H, Marchenay C, Maurizis J C, Madelmont J C, Cholle P, Armand J P: Pharmacokinetic study of cystemustine, administered on a weekly schedule in cancer patients. Ann Oncol 2002, 13:760-769.
13. Kokkinakis D M, von Wronski M A, Vuong T H, Brent T P, Schold S C, Jr.: Regulation of O6-methylguanine-DNA methyltransferase by methionine in human tumour cells. Br J Cancer 1997, 75:779-788.
14. Morvan D, Papon J, Madelmont J C, Demidem A: Methionine deprivation potentiates the effect of cystemustine treatment on B16 melanoma tumors in syngenic recipients. AACR, San Francisco, 2002, 3822.